DE602004025265D1 - Neues phosphatbindendes protein, pharmazeutische zusammensetzungen, die dieses enthalten, und verwendung davon - Google Patents

Neues phosphatbindendes protein, pharmazeutische zusammensetzungen, die dieses enthalten, und verwendung davon

Info

Publication number
DE602004025265D1
DE602004025265D1 DE602004025265T DE602004025265T DE602004025265D1 DE 602004025265 D1 DE602004025265 D1 DE 602004025265D1 DE 602004025265 T DE602004025265 T DE 602004025265T DE 602004025265 T DE602004025265 T DE 602004025265T DE 602004025265 D1 DE602004025265 D1 DE 602004025265D1
Authority
DE
Germany
Prior art keywords
sequence
phosphat
new
pharmaceutical compositions
binding protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602004025265T
Other languages
English (en)
Inventor
Eric Chabriere
Carlos Contreras-Martel
Juan Fontecilla-Camps
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Universite Henri Poincare - Nancy I
Original Assignee
Centre National de la Recherche Scientifique CNRS
Universite Henri Poincare - Nancy I
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Universite Henri Poincare - Nancy I filed Critical Centre National de la Recherche Scientifique CNRS
Publication of DE602004025265D1 publication Critical patent/DE602004025265D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2299/00Coordinates from 3D structures of peptides, e.g. proteins or enzymes
DE602004025265T 2003-10-30 2004-10-29 Neues phosphatbindendes protein, pharmazeutische zusammensetzungen, die dieses enthalten, und verwendung davon Active DE602004025265D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0312729A FR2861731B1 (fr) 2003-10-30 2003-10-30 Nouvelle proteine de fixation du phosphate, compositions pharmaceutiques la contenant et ses utilisations
PCT/FR2004/002797 WO2005042572A1 (fr) 2003-10-30 2004-10-29 Nouvelle proteine de fixation du phosphate, compositions pharmaceutiques la contenant et ses utilisations

Publications (1)

Publication Number Publication Date
DE602004025265D1 true DE602004025265D1 (de) 2010-03-11

Family

ID=34429758

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004025265T Active DE602004025265D1 (de) 2003-10-30 2004-10-29 Neues phosphatbindendes protein, pharmazeutische zusammensetzungen, die dieses enthalten, und verwendung davon

Country Status (11)

Country Link
US (1) US7718773B2 (de)
EP (1) EP1678204B1 (de)
JP (1) JP4728246B2 (de)
CN (1) CN1898261B (de)
AT (1) ATE455792T1 (de)
CA (1) CA2543935C (de)
DE (1) DE602004025265D1 (de)
ES (1) ES2341174T3 (de)
FR (1) FR2861731B1 (de)
IL (1) IL175319A (de)
WO (1) WO2005042572A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7833707B2 (en) * 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
UA95602C2 (ru) 2004-12-30 2011-08-25 Берингер Ингельхейм Ветмедика, Инк. Иммуногенная композиция цвс2 и способы приготовления такой композиции
US7700285B1 (en) 2005-12-29 2010-04-20 Boehringer Ingelheim Vetmedica, Inc. PCV2 immunogenic compositions and methods of producing such compositions
WO2007076520A2 (en) 2005-12-29 2007-07-05 Boehringer Ingelheim Vetmedica, Inc. Multivalent pcv2 immunogenic compositions and methods of producing such compositions
KR20140019479A (ko) 2005-12-29 2014-02-14 베링거잉겔하임베트메디카인코퍼레이티드 돼지에서 임상 증상을 경감시키기 위한 pcv2 면역원성 조성물의 용도
US20100136060A1 (en) * 2006-11-22 2010-06-03 Boehringer Ingelheim Vetmedica, Inc. Methods of reducing porcine circovirus-associated disease outbreaks
EP2859900A1 (de) * 2006-12-11 2015-04-15 Boehringer Ingelheim Vetmedica, Inc. Wirksames Verfahren zur Behandlung von Infektionen mit dem porcinen Circovirus und Lawsonia intracellularis
ES2625460T5 (es) * 2006-12-15 2020-11-04 Boehringer Ingelheim Animal Health Usa Inc Tratamiento de cerdos seropositivos en anticuerpo anti-PCV2 con antígeno de PCV2
EP1941903A1 (de) * 2007-01-03 2008-07-09 Boehringer Ingelheim Vetmedica Gmbh Prophylaxe und Behandlung von PRDC
EP1958644A1 (de) 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Vorbeugung und Behandlung von subklinischer PCVD
US7829274B2 (en) 2007-09-04 2010-11-09 Boehringer Ingelheim Vetmedica, Inc. Reduction of concomitant infections in pigs by the use of PCV2 antigen
CN101932336B (zh) * 2007-12-31 2014-07-09 贝林格尔.英格海姆维特梅迪卡有限公司 有外来氨基酸插入的pcv2 orf2病毒样颗粒
CN101980720A (zh) 2008-01-23 2011-02-23 贝林格尔.英格海姆维特梅迪卡有限公司 Pcv2猪肺炎支原体致免疫组合物及其制备方法
FR2942717B1 (fr) 2009-03-04 2011-08-12 Centre Nat Rech Scient Nouvel agent antiviral
AR078253A1 (es) 2009-09-02 2011-10-26 Boehringer Ingelheim Vetmed Metodos para reducir la actividad antivirica en composiciones pcv-2 y composiciones pcv-2 con mejor inmunogenicidad
WO2014014918A2 (en) * 2012-07-16 2014-01-23 St. Luke's-Roosevelt Hospital Center X-ding-cd4 peptide
EA035265B1 (ru) 2013-10-02 2020-05-21 Бёрингер Ингельхайм Энимал Хелс Ю-Эс-Эй Инк. Вариант белка opc2 pcv2 и содержащие его вирусоподобные частицы

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2334905A1 (en) * 1998-06-12 1999-12-23 Gordon J. Hoover Pattern recognition proteins with lectin homology from several animal species and method to use them for measure or modulate innate resistance against bacteria and other pathogenic agents
US20030158115A1 (en) * 2000-03-28 2003-08-21 Toback F. Gary Methods and compositions for detecting and treating kidney diseases associated with adhesion of crystals to kidney cells

Also Published As

Publication number Publication date
WO2005042572A1 (fr) 2005-05-12
ES2341174T3 (es) 2010-06-16
FR2861731A1 (fr) 2005-05-06
JP2008502305A (ja) 2008-01-31
CN1898261B (zh) 2011-08-17
EP1678204A1 (de) 2006-07-12
FR2861731B1 (fr) 2006-02-24
IL175319A (en) 2013-07-31
JP4728246B2 (ja) 2011-07-20
CA2543935A1 (fr) 2005-05-12
CA2543935C (fr) 2014-12-02
ATE455792T1 (de) 2010-02-15
US20070196879A1 (en) 2007-08-23
US7718773B2 (en) 2010-05-18
CN1898261A (zh) 2007-01-17
EP1678204B1 (de) 2010-01-20
IL175319A0 (en) 2006-09-05

Similar Documents

Publication Publication Date Title
IL175319A0 (en) Novel phosphate-binding protein, pharmaceutical compositions containing same and use thereof
AU2003264419A1 (en) Kdr peptides and vaccines containing the same
IN2015DN02553A (de)
AU2002305450A1 (en) Proteomimetic compounds and methods
DE602005020165D1 (de) Verfahren zur herstellung von l-arginin, l-ornithin oder l-citrullin
EP2039367A4 (de) Prophylaktisches/therapeutisches mittel für neurodegenerative erkrankungen
WO2006028561A3 (en) Novel purified fabi polypeptides from fransicella tularensis
ATE495247T1 (de) Chromoprotein und fluoroproteine
WO2007013358A3 (en) Vivit polypeptides, therapeutic agent comprising the same, and method of screening for anti-cancer agent
ATE551353T1 (de) Protein mit fusogener wirkung, nukleinsäuresequenzen, die für dieses protein codieren und pharmazeutische zusammensetzungen, die dieses enthalten
AU2003251728A1 (en) Placental growth factor as a target for the treatment of osteoporosis
WO2005086595A3 (ja) テロメアタンパク質trf2dna結合ドメイン変異体タンパク質、テロメアdna変異体及びtrf2dna結合ドメインと二重らせんdnaとの複合体構造の利用
WO2004011638A3 (en) Deoxyuridine 5' triphosphate nucleotidohydrolase polypeptides and structures
PT1401871E (pt) Moleculas de ligacao imunologicas que inibem a fusao sincicial de celulas do tropoblasto
WO2004013167A3 (en) Purified polypeptides from enterococcus faecalis
WO2005087809B1 (en) Peptides from vitronectin and their therapeutic exploitation for osteoblast adhesion
WO2009014160A1 (ja) 膵癌の新規腫瘍マーカー
WO2004081165A3 (en) Novel purified dihydrodipicolinate synthase polypeptides and structures thereof
NZ603077A (en) Biological materials and uses thereof
WO2004042044A3 (en) Crystal structures of bacterial guanylate kinases

Legal Events

Date Code Title Description
8364 No opposition during term of opposition